CY1121081T1 - Samidorphan (alks 33) σε συνδυασμο με βουπρενορφινη για την θεραπεια καταθλιπτικων διαταραχων - Google Patents

Samidorphan (alks 33) σε συνδυασμο με βουπρενορφινη για την θεραπεια καταθλιπτικων διαταραχων

Info

Publication number
CY1121081T1
CY1121081T1 CY181101356T CY181101356T CY1121081T1 CY 1121081 T1 CY1121081 T1 CY 1121081T1 CY 181101356 T CY181101356 T CY 181101356T CY 181101356 T CY181101356 T CY 181101356T CY 1121081 T1 CY1121081 T1 CY 1121081T1
Authority
CY
Cyprus
Prior art keywords
samidorphan
buprenorphin
alks
treatment
combination
Prior art date
Application number
CY181101356T
Other languages
English (en)
Inventor
Daniel Deaver
Elliot Ehrich
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of CY1121081T1 publication Critical patent/CY1121081T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η εφεύρεση αφορά μια σύνθεση που περιλαμβάνει βουπρενοφρίνη και έναν ανταγωνιστή υποδοχέα οπιούχων μ, όπου η σύνθεση χαρακτηρίζεται από έναν δείκτη δραστηριότητας ανταγωνιστών:αγωνιστών (AAnAI) μεταξύ περίπου 0.7 και περίπου 2.2 όπου = AAnAI/EC50 c max BUP c max ανταγωνιστή / IC 50.
CY181101356T 2011-12-15 2018-12-18 Samidorphan (alks 33) σε συνδυασμο με βουπρενορφινη για την θεραπεια καταθλιπτικων διαταραχων CY1121081T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161576233P 2011-12-15 2011-12-15
PCT/IB2012/002900 WO2013088243A1 (en) 2011-12-15 2012-12-14 Compositions of buprenorphine and mu-opioid receptor antagonists
EP12830900.2A EP2790702B1 (en) 2011-12-15 2012-12-14 Compositions of buprenorphine and mu-opioid receptor antagonists

Publications (1)

Publication Number Publication Date
CY1121081T1 true CY1121081T1 (el) 2019-12-11

Family

ID=47757653

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181101356T CY1121081T1 (el) 2011-12-15 2018-12-18 Samidorphan (alks 33) σε συνδυασμο με βουπρενορφινη για την θεραπεια καταθλιπτικων διαταραχων

Country Status (24)

Country Link
US (8) US8822488B2 (el)
EP (3) EP3153171B1 (el)
JP (2) JP6038170B2 (el)
KR (1) KR101996108B1 (el)
CN (2) CN106727562B (el)
AU (1) AU2012351806C1 (el)
BR (1) BR112014012409B8 (el)
CA (1) CA2858812C (el)
CY (1) CY1121081T1 (el)
DK (1) DK3153171T3 (el)
EA (1) EA030609B8 (el)
ES (2) ES2692771T3 (el)
HR (1) HRP20181950T1 (el)
HU (1) HUE041883T2 (el)
IL (1) IL232785B (el)
LT (1) LT3153171T (el)
MX (1) MX2014007042A (el)
PL (1) PL3153171T3 (el)
PT (1) PT3153171T (el)
RS (1) RS58322B1 (el)
SI (1) SI3153171T1 (el)
TR (1) TR201815154T4 (el)
WO (1) WO2013088243A1 (el)
ZA (1) ZA201405029B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03468B (me) 2009-12-04 2020-01-20 Alkermes Pharma Ireland Ltd Derivati morfinana za liječenje predoziranja lijekom
AU2011293502B2 (en) 2010-08-23 2015-03-19 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
KR101996108B1 (ko) 2011-12-15 2019-10-01 엘커메스 파마 아일랜드 리미티드 부프레놀핀 및 뮤-오피오이드 수용체 길항물질의 조성물
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
AU2014268361B2 (en) 2013-05-24 2018-09-06 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
WO2014190271A2 (en) 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limted Methods for treating depressive symptoms
AR103598A1 (es) 2015-02-02 2017-05-24 Forma Therapeutics Inc Ácidos bicíclicos[4,6,0]hidroxámicos como inhibidores de hdac
ES2770123T3 (es) 2015-02-02 2020-06-30 Forma Therapeutics Inc Acidos 3-alquil-4-amido-bicíclicos [4,5,0]hidroxámicos como inhibidores de HDAC
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH581624A5 (el) 1970-08-14 1976-11-15 Sumitomo Chemical Co
US3856795A (en) 1972-04-25 1974-12-24 American Home Prod Process for preparation of secondary amines from tertiary amines
US3957793A (en) 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
US4032529A (en) 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US4127577A (en) 1975-11-24 1978-11-28 Sterling Drug Inc. Aminomethanobenzazocine process
US4205171A (en) 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4649200A (en) 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
US4939264A (en) 1986-07-14 1990-07-03 Abbott Laboratories Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
US5258386A (en) 1991-06-05 1993-11-02 The United States Of America As Represented By The Secretary Of The Army (+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents
US5607941A (en) 1992-06-26 1997-03-04 Boehringer Ingelheim Kg Useful for treating neurodegenerative diseases
SE9103745D0 (sv) 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
EP0632041A1 (en) 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
JP2000503019A (ja) 1996-01-10 2000-03-14 スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ 複素環縮合モルフィノイド誘導体（ｉｉ）
GB9709972D0 (en) 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
US7534866B2 (en) * 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
DE60133584T2 (de) 2000-10-31 2009-06-04 Rensselaer Polytechnic Institute 4-arylpiperidine als opioidrezeptorbindende agenzien
ES2305457T3 (es) * 2002-03-20 2008-11-01 Euro-Celtique S.A. Metodo de administracion de buprenorfina para tratar la depresion.
WO2003101963A1 (en) 2002-05-30 2003-12-11 Eli Lilly And Company Opioid receptor antagonists
AU2005245403B2 (en) 2004-05-14 2012-04-19 Janssen Pharmaceutica N.V. Carboxamido opioid compounds
US20060063792A1 (en) * 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
ATE557006T1 (de) 2004-11-05 2012-05-15 Rensselaer Polytech Inst 4-hydroxybenzomorphane
NZ589278A (en) 2005-03-02 2012-04-27 Nycomed Gmbh Selected salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives
CA2681506C (en) 2007-03-19 2016-05-24 Perry Peters Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
MX2010001371A (es) 2007-08-09 2010-03-10 Rensselaer Polytech Inst Carboxamidas opioides cuaternarias.
AU2009214500B2 (en) * 2008-02-14 2014-10-23 Alkermes, Inc. Selective opioid compounds
WO2009126931A2 (en) 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
CA2754984C (en) * 2009-03-19 2018-06-26 Alkermes, Inc. Morphinan derivatives with high oral bioavailability
WO2010141666A2 (en) 2009-06-04 2010-12-09 The General Hospital Corporation Modulating endogenous beta-endorphin levels
US8530479B2 (en) * 2009-08-10 2013-09-10 Daljit Singh Dhanoa Deuterium-enriched alkyl sulfonamides
ME03468B (me) 2009-12-04 2020-01-20 Alkermes Pharma Ireland Ltd Derivati morfinana za liječenje predoziranja lijekom
KR101996108B1 (ko) * 2011-12-15 2019-10-01 엘커메스 파마 아일랜드 리미티드 부프레놀핀 및 뮤-오피오이드 수용체 길항물질의 조성물
US9211293B2 (en) * 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
WO2014190271A2 (en) * 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limted Methods for treating depressive symptoms

Also Published As

Publication number Publication date
BR112014012409B8 (pt) 2022-09-13
US9918978B2 (en) 2018-03-20
AU2012351806B2 (en) 2016-03-10
JP6403726B2 (ja) 2018-10-10
NZ624056A (en) 2016-07-29
US20160256450A1 (en) 2016-09-08
JP2016222706A (ja) 2016-12-28
EA030609B8 (ru) 2018-10-31
EP3153171A1 (en) 2017-04-12
US20180078543A1 (en) 2018-03-22
ZA201405029B (en) 2015-10-28
EP3415148A1 (en) 2018-12-19
HRP20181950T1 (hr) 2019-03-22
RS58322B1 (sr) 2019-03-29
DK3153171T3 (en) 2018-11-19
US8822488B2 (en) 2014-09-02
HUE041883T2 (hu) 2019-06-28
IL232785A0 (en) 2014-07-31
ES2692771T3 (es) 2018-12-05
US10188643B2 (en) 2019-01-29
JP2015505853A (ja) 2015-02-26
EA201491153A1 (ru) 2015-04-30
US10314838B2 (en) 2019-06-11
US9913837B2 (en) 2018-03-13
KR20140107258A (ko) 2014-09-04
TR201815154T4 (tr) 2018-11-21
JP6038170B2 (ja) 2016-12-07
WO2013088243A1 (en) 2013-06-20
CA2858812C (en) 2019-02-26
ES2791764T3 (es) 2020-11-05
IL232785B (en) 2021-04-29
US20180078542A1 (en) 2018-03-22
BR112014012409B1 (pt) 2022-08-23
US20150051240A1 (en) 2015-02-19
US20190247387A1 (en) 2019-08-15
AU2012351806C1 (en) 2016-06-16
CN106727562A (zh) 2017-05-31
EP2790702B1 (en) 2020-04-01
LT3153171T (lt) 2018-12-10
EP3153171B1 (en) 2018-09-19
CN106727562B (zh) 2019-07-05
EP2790702A1 (en) 2014-10-22
CA2858812A1 (en) 2013-06-20
US10806731B2 (en) 2020-10-20
PL3153171T3 (pl) 2019-02-28
US9498474B2 (en) 2016-11-22
EA030609B1 (ru) 2018-08-31
KR101996108B1 (ko) 2019-10-01
US20130190342A1 (en) 2013-07-25
US20170056392A1 (en) 2017-03-02
AU2012351806A1 (en) 2014-05-15
PT3153171T (pt) 2018-11-16
BR112014012409A2 (pt) 2017-06-13
MX2014007042A (es) 2015-01-22
US20210196703A1 (en) 2021-07-01
SI3153171T1 (sl) 2019-01-31
CN104159586A (zh) 2014-11-19

Similar Documents

Publication Publication Date Title
CY1121081T1 (el) Samidorphan (alks 33) σε συνδυασμο με βουπρενορφινη για την θεραπεια καταθλιπτικων διαταραχων
CY1123365T1 (el) Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα
CY1123590T1 (el) Θεραπειες που βασιζονται σε προσδετη χημειοαισθητηριου υποδοχεα
EA201300869A1 (ru) Морфинановые соединения
CY1117696T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΚΥΚΛΟΕΞΥΛΑΜΙΝΗΣ ΜΕ ΔΡΑΣΕΙΣ β2 ΑΔΡΕΝΕΡΓΙΚΟΥ ΑΓΩΝΙΣΤΗ ΚΑΙ Μ3 ΜΟΥΣΚΑΡΙΝΙΚΟΥ ΑΝΤΑΓΩΝΙΣΤΗ
MY169479A (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CY1118352T1 (el) Νεα παραγωγα κυκλοεξυλαμινης με δρασεις β2 αδρενεργικου αγωνιστη και μ3 μουσκαρινικου ανταγωνιστη
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
DK2522667T3 (da) Morphinanforbindelser
ECSP14003642A (es) 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
CY1119047T1 (el) Υποκατεστημενα βενζαμιδια με δραστικοτητα εναντι υποδοχεων ερ4
MX342161B (es) Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3.
CY1119800T1 (el) Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων
EA201071169A1 (ru) ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3
CY1120661T1 (el) Ανταγωνιστες υποδοχεα 5-ητ3 σεροτονινης για χρηση στη θεραπεια των αλλοιωτικων αιθουσαιων διαταραχων
CO6341558A2 (es) Antagonistas del recepptor de nmda para el tratamiento de trastornos neuropsiquiatricos
EA201490161A1 (ru) Соединения - ингибиторы сигналинга, опосредуемого рецептором notch
MX2013005246A (es) Antagonistas del receptor del peptido relacionado con el gen de calcitonina (cgrp) de piperidinona carboxamida azaindano.
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
EA201301114A1 (ru) Ингибитор фосфоинозитид-3-киназы, содержащий цинксвязывающий фрагмент
MX2015013328A (es) Uso de antagonistas del receptor de ep4 en el tratamiento de enfermedad de cartilago.
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique
ATE557019T1 (de) Pyrrolidin-3-ylmethyl-amin als orexin- antagonisten
EA201290851A1 (ru) Способы и композиции для лечения или предупреждения симптомов гормональных изменений